| 000 | 01828 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516090210.0 | ||
| 264 | 0 | _c20120918 | |
| 008 | 201209s 0 0 eng d | ||
| 022 | _a1528-0020 | ||
| 024 | 7 |
_a10.1182/blood-2012-02-409185 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCollins, Peter | |
| 245 | 0 | 0 |
_aImmunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). _h[electronic resource] |
| 260 |
_bBlood _cJul 2012 |
||
| 300 |
_a47-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAutoantibodies _ximmunology |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclosporine _xadministration & dosage |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 |
_aFactor VIII _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHemophilia A _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRegistries _xstatistics & numerical data |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 |
_aSteroids _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBaudo, Francesco | |
| 700 | 1 | _aKnoebl, Paul | |
| 700 | 1 | _aLévesque, Hervé | |
| 700 | 1 | _aNemes, László | |
| 700 | 1 | _aPellegrini, Fabio | |
| 700 | 1 | _aMarco, Pascual | |
| 700 | 1 | _aTengborn, Lilian | |
| 700 | 1 | _aHuth-Kühne, Angela | |
| 773 | 0 |
_tBlood _gvol. 120 _gno. 1 _gp. 47-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2012-02-409185 _zAvailable from publisher's website |
| 999 |
_c21717080 _d21717080 |
||